Mesenchymal Cell News Volume 4.05 | Feb 7 2012

Direct and Efficient Cellular Transformation of Primary Rat Mesenchymal Precursor Cells by KSHV
Here, researchers report efficient infection and cellular transformation of primary rat embryonic metanephric mesenchymal precursor cells by kaposi’s sarcoma-associated herpesvirus (KSHV). [J Clin Invest]
Abstract | Press Release

Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche through the CCL2-Dependent Recruitment and Polarization of Monocytes
Researchers show here that bone marrow-mesenchymal stromal cells (MSC) obtained from follicular lymphoma patients display a specific gene expression profile compared to MSC obtained from healthy age-matched donors. [Blood] Abstract

Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma
Overexpression of growth differentiation factor 15 (GDF15) by bone marrow mesenchymal stem cells occurs widely in patients with multiple myeloma (MM), but the pathophysiological effects of GDF15 in this setting remain undefined. In this study, researchers report that GDF15 significantly increases survival of stroma-dependent MM cells including primary MM cells. [Cancer Res] Abstract

A Calcium-Induced Signaling Cascade Leading to Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stromal Cells
Here, researchers have created an in vitro environment with high extracellular calcium concentration and investigated the response of human bone marrow-derived mesenchymal stromal cells to it. [Biomaterials] Abstract

Adipose Tissue-Derived Mesenchymal Stem Cells Improve Revascularization Outcomes to Restore Renal Function in Swine Atherosclerotic Renal Artery Stenosis
Researchers hypothesized that replenishment of mesenchymal stem cells as an adjunct to percutaneous transluminal renal angioplasty would restore renal cellular integrity and improve renal function in atherosclerotic renal artery stenosis pigs. [Stem Cells] Abstract

Potently Immunosuppressive 5-Fluorouracil-Resistant Mesenchymal Stromal Cells Completely Remit an Experimental Autoimmune Disease
Researchers treated mice with 5-fluorouracil (5-FU) to isolate a quiescent and undifferentiated mesenchymal stromal cell (MSC) population from the bone marrow. These 5-FU-resistant MSCs free from hematopoietic components were examined for CFU fibroblasts and their immunosuppressive potential in vitro and in vivo was assessed. [J Immunol] Abstract

Short-Term Exposure to Tumor Necrosis Factor-α Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation
Researchers demonstrate that the p38 mitogen-activated protein kinase signaling pathway regulates the expression of bone morphogenetic protein-2 in osteoblasts, which then acts through a paracrine loop, to direct the osteoblast lineage commitment of mesenchymal stem cells. [Stem Cells Dev] Abstract

Hypoxic Preconditioning Enhances Survival of Human Adipose-Derived Stem Cells and Conditions Endothelial Cells In Vitro
Here researchers report the protective effects of hypoxic preconditioning and identify mechanisms for improving survival of adipose-derived stem cells in vitro. [Stem Cells Dev] Abstract

Mesoblast Receives FDA Clearance for Phase II Clinical Trial of Proprietary Stem Cell Therapy in Type 2 Diabetes
Mesoblast Limited announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase II clinical trial of its proprietary adult stem cells for the treatment of type 2 diabetes. [Mesoblast Limited] Press Release

TiGenix Rheumatoid Arthritis Phase IIa Study Opens Third and Last Cohort
TiGenix announced that upon review of the safety data of the first three patients of the second cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining 20 patients of this cohort and to open the third and final cohort. [TiGenix] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 18th Annual International Society for Cellular Therapy Meeting
June 5-8, 2012
Seattle, United States

NEW 6^th International Conference on Human Leukocyte Antigen-G
July 9-11, 2012
Paris, France

Visit our events page to see a complete list of events in the mesenchymal cell community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Positions – Stem Cell Biology (Columbia University)

Research Associates/Scientist/Senior Scientist – Stem Cell Research (Advanced Cell Technology) 

PhD Student – Immunotherapy Using Mesenchymal Stem Cells (Charles University)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.